In breast cancer, neuroblastoma, hepatocellular carcinoma, and lung adenocarcinoma, higher expression levels of GABARAPL1 correlate with reduced risk of tumor metastasis and improved patient survival rates. This evidence concerns the gene GABARAPL1 and hepatocellular carcinoma.